Skip to main content

Monte Rosa Therapeutics, Inc.

GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826457

In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.

Q3 2022 vs. Q2 2022

How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of GLUE: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders5770+13
Shares38.8M40.3M+1.48M (+3.8%)
Value$375.0M$328.8M−$46.2M (−12.3%)

New holders (16)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to GLUE in Q3 2022
InstitutionSharesValue% of portfolio
T. Rowe Price Investment Management, Inc.1,924,778$15.7M0.01%
OrbiMed Advisors LLC117,455$960.0K0.02%
HRT Financial LP85,798$700.0K0.01%
Jane Street Group, LLC50,222$410.0K0.00%
Trexquant Investment LP41,600$340.0K0.01%
Cubist Systematic Strategies, LLC32,406$265.0K0.00%
Cornercap Investment Counsel Inc28,192$230.0K0.04%
Gsa Capital Partners LLP19,084$156.0K0.02%
Balyasny Asset Management LLC19,031$155.0K0.00%
Jump Financial, LLC18,200$149.0K0.01%
Mirae Asset Global Investments Co., Ltd.13,112$108.0K0.00%
Ameriprise Financial Inc13,086$107.0K0.00%
Virtus Investment Advisers, Inc.12,638$103.0K0.05%
Invesco Ltd.10,003$81.0K0.00%
Russell Investments Group, Ltd.1,431$11.0K0.00%
China Universal Asset Management Co., Ltd.437$4.00K0.00%

Sold out (3)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of GLUE in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Allianz Asset Management GmbH121,750$1.18M
SG Americas Securities, LLC11,319$109.0K
Ensign Peak Advisors, Inc240$2.00K